TGFB1 and neoplasm: Previous studies have found that in mice using specific models, combined treatment with blockade of TGF-β and anti-PD-L1 antibodies restrained signaling of TGF-β in stromal cells, promoting T cell recruitment to tumor centers and subsequently provoking a robust antitumor immune response (224, 255).